Moneycontrol PRO
you are here: HomeNewsBusiness

White-collar job losses may rise with mega-mergers in US, warns Goldman Sachs

The comments by Goldman Sachs Group President John Waldron arrived a few weeks ahead of the US Presidential Elections 2020, when stalled stimulus talks and economic fallout due to the COVID-19 pandemic, are threatening to undermine job recovery

October 17, 2020 / 10:31 PM IST

Amid the coronavirus pandemic and the economic crisis prevailing globally, the Wall Street’s top matchmaker for mega deals has sighted a wave of corporate takeovers in the US, with worrying implication for the workforce which may see a jump in white-collar job losses.

"Politicians are going to be faced with the uncomfortable reality that you’re going to have more big business doing better and that there’s going to be more losses of jobs along the way," Bloomberg quoted Goldman Sachs Group president John Waldron as saying.

Waldron also noted that the possibility of a sizable amount of large-cap M&A coming with stronger, healthier companies being the acquirer and taking advantage of weaknesses in their industry or elsewhere is bright.

The comments by Waldron, Goldman’s second-in-command, arrived a few weeks ahead of the US Presidential Elections 2020, when stalled stimulus talks and economic fallout due to the COVID-19 pandemic are threatening to undermine job recovery.

Waldron even opined that 'sticky unemployment' may gain momentum once companies combine.


COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

Exclusive | Goldman Sachs Private Equity in talks to buy minority stake in IPO-bound Biocon Biologics.

"Our clients are more desirous of playing offence and doing deals. That’s a good thing. But that includes large companies looking to consolidate smaller companies, and that will be complicated societally," he added.

This year, when most of the firms' financial position shook, Goldman Sachs has been one of the biggest beneficiaries. Its core Wall Street trading and dealmaking operations facing a surge in demand from investors and corporations who are looking forward to repositioning themselves or raise capital.

According to Labor Department data, released on October 15, around 898,000 Americans filed for first-time unemployment benefits last week.
Moneycontrol News

stay updated

Get Daily News on your Browser
ISO 27001 - BSI Assurance Mark